Changes in the EGFR amplification and EGFRvIII expression between paired primary and recurrent glioblastomas

Neuro-Oncology

Volumn 17, Issue 7, 2015, Pages 935-941

  Van Den Bent, Martin J ^a   Gao, Ya ^a   Kerkhof, Melissa ^b   Kros, Johan M ^a   Gorlia, Thierry ^c   Van Zwieten, Kitty ^a   Prince, Jory ^a   Van Duinen, Sjoerd ^d   Sillevis Smitt, Peter A ^a   Taphoorn, Martin ^b   French, Pim J ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b Haaglanden MC   (Netherlands)

^c EORTC DATA CENTER   (Belgium)

^d LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

EGFR; EGFRvIII; glioblastoma; recurrent tumors

Indexed keywords

DNA; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 8; RNA; TEMOZOLOMIDE; UNCLASSIFIED DRUG; EGFR PROTEIN, HUMAN; EPIDERMAL GROWTH FACTOR RECEPTOR VIII;

ADULT; AGED; ARTICLE; CANCER RECURRENCE; CANCER SURGERY; CANCER TISSUE; CHEMORADIOTHERAPY; CONTROLLED STUDY; EGFR GENE; FEMALE; GENE AMPLIFICATION; GENE EXPRESSION; GENE LOCUS; GENE MUTATION; GLIOBLASTOMA; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; BRAIN TUMOR; DIAGNOSIS; GENETICS; METABOLISM; MIDDLE AGED; TUMOR RECURRENCE;

ADULT; AGED; BRAIN NEOPLASMS; FEMALE; GENE AMPLIFICATION; GLIOBLASTOMA; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 84936762102     PISSN: 15228517     EISSN: 15235866     Source Type: Journal    
DOI: 10.1093/neuonc/nov013     Document Type: Article

References (23)

1. Louis DN, Ohgaki H, Wiestler OD, et al. WHO Classification of Tumours of the Central Nervous System. 4th ed. Lyon: The World Health Organization; 2007.
2. Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352(10):987-996.
3. Gorlia T, Stupp R, Brandes AA, et al. New prognostic factors and calculators for outcome prediction in patients with recurrent glioblastoma: A pooled analysis of EORTC Brain Tumour Group phase I and II clinical trials. Eur J Cancer. 2012;48(8):1176-1184.
4. Bettegowda C, Sausen M, Leary RJ, et al. Detection of circulating tumor DNA in early-and late-stage human malignancies. Sci Transl Med. 2014;6(224):224-224.
5. Johnson BE, Mazor T, Hong C, et al. Mutational analysis reveals the origin and therapy-driven evolution of recurrent glioma. Science. 2014;343(6167):189-193.
6. Brennan CW, Verhaak RG, McKenna A, et al. The somatic genomic landscape of glioblastoma. Cell. 2013;155(2):462-477.
7. Parsons DW, Jones S, Zhang X, et al. An integrated genomic analysis of human glioblastoma multiforme. Science. 2008; 321(5897):1807-1812.
8. Rich JN, Reardon DA, Peery T, et al. Phase II trial of gefitinib in recurrent glioblastoma. J Clin Oncol. 2004;22(1):133-142.
9. van den Bent MJ, Brandes AA, Rampling R, et al. Randomized phase II trial of erlotinib versus temozolomide or carmustine in recurrent glioblastoma: EORTC brain tumor group study 26034. J Clin Oncol. 2009;27(8):1268-1274.
10. Vivanco I, Robins HI, Rohle D, et al. Differential sensitivity of glioma-versus lung cancer-specific EGFR mutations to EGFR kinase inhibitors. Cancer Discov. 2012;2(5):458-471.
11. Gan HK, Fichtel L, Lassman AB, et al. A phase 1 study evaluating ABT-414 in combination with temozolomide (TMZ) for subjects with recurrent or unresectable glioblastoma (GBM). J Clin Oncol. 2014;32(5S):2021.
12. Sampson JH, Heimberger AB, Archer GE, et al. Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma. J Clin Oncol. 2010; 28(31):4722-4729.
13. Frederick L, Eley G, Wang XY, et al. Analysis of genomic rearrangements associated with EGRFvIII expression suggests involvement of Alu repeat elements. Neuro Oncol. 2000;2(3): 159-163.
14. Lin LI. A concordance correlation coefficient to evaluate reproducibility. Biometrics. 1989;45(1):255-268.
15. Hobbs J, Nikiforova MN, Fardo DW, et al. Paradoxical relationship between the degree of EGFR amplification and outcome in glioblastomas. Am J Surg Pathol. 2012;36(8):1186-1193.
16. Gravendeel LA, Kouwenhoven MC, Gevaert O, et al. Intrinsic gene expression profiles of gliomas are a better predictor of survival than histology. Cancer Res. 2009;69(23):9065-9072.
17. Erdem-Eraslan L, Gravendeel LA, de Rooi J, et al. Intrinsicmolecular subtypes of glioma are prognostic and predict benefit from adjuvant procarbazine, lomustine, and vincristine chemotherapy in combination with other prognostic factors in anaplastic oligodendroglial brain tumors: A report from EORTC study 26951. J Clin Oncol. 2013;31(3):328-336.
18. Montano N, Cenci T, Martini M, et al. Expression of EGFRvIII in glioblastoma: Prognostic significance revisited. Neoplasia. 2011; 13(12):1113-1121.
19. Del Vecchio CA, Giacomini CP, Vogel H, et al. EGFRvIII gene rearrangement is an early event in glioblastoma tumorigenesis and expression defines a hierarchy modulated by epigenetic mechanisms. Oncogene. 2013;32(21):2670-2681.
20. Francis JM, Zhang CZ, Maire CL, et al. EGFR variant heterogeneity in glioblastoma resolved through single-nucleus sequencing. Cancer Discov. 2014;4(8):956-971.
21. Snuderl M, Fazlollahi L, Le LP, et al. Mosaic amplification of multiple receptor tyrosine kinase genes in glioblastoma. Cancer Cell. 2011; 20(6):810-817.
22. Nathanson DA, Gini B, Mottahedeh J, et al. Targeted therapy resistance mediated by dynamic regulation of extrachromosomal mutant EGFR DNA. Science. 2014;343(6166):72-76.
23. Szerlip NJ, Pedraza A, Chakravarty D, et al. Intratumoral heterogeneity of receptor tyrosine kinases EGFR and PDGFRA amplification in glioblastoma defines subpopulations with distinct growth factor response. Proc Natl Acad Sci USA. 2012; 109(8):3041-3046.